Description: Carfilzomib (PR-171) is a proteasome inhibitor that irreversibly binds to the chymotrypsin of the 20S proteasome. Carfilzomib has antitumor activity and may be used to treat multiple myeloma. Target: Proteasome, Autophagy, Apoptosis. Smiles:...

Carfilzomib is a second-generation, irreversible, peptide epoxyketone class proteasome inhibitor that targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50 = 5.2 nM) and the beta5i subunit of the immunoproteasome 20Si (LMP7, IC50 = 14 nM) with minimal cross reactivity to other...

Carfilzomib, a tetrapeptide epoxyketone, is an epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S proteasome, an enzyme responsible for degrading a large variety of cellular proteins.

Synthetic. Chemical. CAS: 868540-17-4. Formula: C40H57N5O7. MW: 719.9. Synthetic. Potent and irreversible second-generation peptide epoxyketone class proteasome inhibitor. Synthetic analog of the microbial product epoxomcin. Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=5.2nM)...